Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
Lite Strategy, Inc., formerly MEI Pharma, reports developments tied to its transition from a clinical-stage pharmaceutical issuer into a public-company digital asset treasury business. News has centered on the adoption of Litecoin (LTC) as the company’s primary treasury reserve asset, the completed corporate rebrand and Nasdaq ticker change from MEIP to LITS, and capital actions used to fund the strategy.
Company updates also cover treasury-management relationships, governance changes, and historical MEI Pharma disclosures involving cash preservation, strategic alternatives, and oncology drug candidates such as voruciclib and ME-344.
MEI Pharma, Inc. (NASDAQ: MEIP) reported its Q1 FY2021 results, highlighting a cash position of $176.1 million with no debt and a net loss of $2.1 million, or $0.02 per share. Revenues increased to $3.8 million from $1.2 million YoY, mainly due to a license agreement with Kyowa Kirin. R&D expenses rose to $13.0 million, driven by zandelisib development. The TIDAL study for follicular lymphoma is on track for enrollment completion by Q1 2021, with additional studies planned for expansion. The company remains committed to advancing its clinical pipeline amid the ongoing pandemic.
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on cancer therapies, announced its participation in two upcoming virtual investor conferences. The conferences include the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 4:40 p.m. ET and the Evercore ISI HealthCONx Conference on December 3, 2020, at 11:45 p.m. ET. Webcasts for both presentations will be available on their website. MEI's portfolio features zandelisib, currently in a Phase 2 trial, which may support FDA accelerated approval.
MEI Pharma announced that the first patient has been dosed in the pivotal Phase 2 study of zandelisib for treating indolent B-cell non-Hodgkin's lymphoma (iNHL) in Japan. This multicenter, open-label study will assess zandelisib as a monotherapy for patients who have undergone at least two prior systemic therapies. The primary endpoint is the objective response rate with a sample size of 60 patients, aiming for completion by September 2024. This marks a significant step in the global development program for zandelisib, following a global licensing agreement with Kyowa Kirin.
Kyowa Kirin and MEI Pharma announced that the first patient has been dosed in a pivotal Phase 2 study of zandelisib in Japan. This multicenter, open-label trial aims to evaluate zandelisib as a monotherapy for patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma (iNHL). In partnership, both companies seek to expand zandelisib's global development, with Kyowa Kirin holding exclusive rights outside the U.S. The study will include 60 patients, primarily measuring the objective response rate, and is expected to conclude by September 2024.
MEI Pharma, Inc. (NASDAQ: MEIP) has appointed Brian T. Powl as Senior Vice President of Marketing, effective immediately. Mr. Powl, previously with Celgene Corporation, brings extensive experience in commercial strategy for cancer therapies. His role will be pivotal as MEI prepares for the potential launch of zandelisib, a drug currently in Phase 2 trials that could receive FDA accelerated approval. COO David Urso emphasized the importance of Powl's leadership in enhancing MEI's commercialization capabilities and achieving long-term growth objectives.
MEI Pharma, Inc. (NASDAQ: MEIP) reported its fiscal year 2020 results, highlighting progress in its cancer treatment zandelisib. The company entered a global collaboration with Kyowa Kirin, receiving a $100 million upfront payment and potential milestones of $582.5 million. Zandelisib showed an 83% response rate in a Phase 1b study for B-cell malignancies. Financially, MEI ended the year with $182.6 million in cash, but reported a net loss of $46 million, or $0.51 per share. As of June 30, 2020, shares outstanding rose to 111,513,689 from 73,544,576 year-over-year.
MEI Pharma, Inc. (NASDAQ: MEIP) announced its participation in three upcoming virtual investor conferences. The events include:
- Wells Fargo 2020 Virtual Healthcare Conference on September 10, 2020, at 2:40 p.m. ET
- H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14, 2020, at 12:00 p.m. ET
- Cantor Virtual Global Healthcare Conference on September 17, 2020, at 4:00 p.m. ET
Each presentation will be available via a live webcast on MEI Pharma's website, with an archive accessible for 30 days post-event.
MEI Pharma, Inc. (NASDAQ: MEIP) will announce its fiscal year 2020 financial results on September 9, 2020, after market close. A conference call and webcast will follow at 5:00 p.m. ET, providing investors with an update on the company and its ongoing clinical trials, including the Phase 2 trial for ME-401, which may support accelerated FDA approval. MEI Pharma is focused on developing new cancer therapies and has a pipeline of four clinical-stage drug candidates.
MEI Pharma, Inc. (NASDAQ: MEIP) announced that CEO Daniel P. Gold, Ph.D., will present a company overview at the BTIG Virtual Biotechnology Conference 2020 on August 11 at 11:00 AM ET. The event will showcase MEI's focus on developing innovative cancer therapies, including the ongoing Phase 2 trial for ME-401. The presentation will be accessible via a live webcast on MEI’s website, followed by an archived replay available for 30 days. MEI Pharma continues to address unmet medical needs in oncology with its diverse portfolio of clinical-stage candidates.